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Abstract. Placental histopathology was studied in a cohort of 204 women living in an area of low Plasmodium
falciparum and P. vivax malaria transmission. Detection of malaria antenatally was active, by weekly peripheral blood
smears, and all infections were treated. Significant histopathologic placental malaria changes (increased malaria pigment,
cytotrophoblastic prominence, and presence of parasites) were found only in a minority of women who had P. falciparum
infections in pregnancy. These changes were significantly more frequent in women with evidence of peripheral blood
infection close to delivery and only in these cases were placental inflammatory cells increased. Antenatal P. vivax
infection was associated only with the presence of malaria pigment in the placenta. All placental infections diagnosed
by blood smear and 32.4% (12 of 37) diagnosed by histopathology were associated with patent peripheral parasitemia.
This study indicates that prompt treatment of peripheral parasitemias during pregnancy limits placental pathology. The
effect on birth weight reduction may not result from irreversible placental changes but from the acute insult of infection.
These findings emphasize the importance of treating malaria in pregnancy promptly with effective antimalarial drugs.
INTRODUCTION
The harmful effects of Plasmodium falciparum infection on
the mother and baby are well recognized.1 Falciparum ma-
laria during pregnancy reduces birth weight, and low birth
weight is a major determinant of infant mortality.2,3 The ma-
jority of studies have come from areas of high stable trans-
mission where infection is almost continuous, the mother is
often asymptomatic (although more anemic), and the pla-
centa heavily parasitized despite low parasitemias in the pe-
ripheral blood. Malaria-related reduction in birth weight pre-
dominantly affects primigravida. The dynamics of malaria in
pregnancy in areas of low and unstable transmission are very
different. In these areas, there is little or no background im-
munity, the majority of infections become symptomatic, and
in falciparum malaria, severe or lethal infections may de-
velop. Symptomatic malaria is treated, or malaria is detected
actively by routine screening at antenatal clinics. This consid-
erably limits the infections and reduces the risk of maternal
death. Despite these brief self-limiting illnesses, the birth
weight reductions are similar to those in high transmission
settings even with a single infection episode of P. falciparum,
and maternal anemia is a common consequence.4 Similar ad-
verse effects have been reported in P. vivax infections, al-
though the reduction in birth weight and anemia are less se-
vere than for P. falciparum infections.5,6 Multigravid women
are also affected: indeed in P. vivax infections, the reduction
in birth weight is greater in multigravids.5
Several studies from Africa7−18 and one from India6, all of
which were conducted in moderate to high transmission ar-
eas, have associated malaria-related histopathologic changes
with poor birth indicators: predominantly low birth weight.
Among these reports, only one study offered pregnant women
prospective antenatal malaria screening and an open door
fever clinic,17 rather than simply enrolling women at the time
of delivery. This study, now more than 20 years old, included
65 women from The Gambia seen at least every six weeks
(February 1979−August 1980) during pregnancy who were
treated for slide-confirmed malaria with chloroquine and who
had placental histology examined after delivery. For the re-
mainder of the studies, the individual antecedent malaria epi-
sodes (rather than fever episodes) and antimalarial drug use
(self-treatment, chemoprophylaxis, and treatment) while
pregnant, are not detailed, although there is usually a general
comment about antimalarial drug use.
There are also a few reports that describe small numbers of
non-falciparum Plasmodium parasites in placental smears.19−22
There are no prospective studies of the placental histopatho-
logic changes associated with malaria in pregnancy in areas
of low transmission and no studies of the pathologic effects of
P. vivax in pregnancy.
This paper reports on the histopathologic features of the
placenta in a cohort of women followed prospectively and
intensively, in an area of seasonal low malaria transmission
where all four species of human malaria occur and both P.
falciparum and P. vivax are prevalent. Women had weekly
blood smears and all positive peripheral parasitemias were
treated with appropriate antimalarials. Findings are reported
for women who were treated for P. falciparum, P. vivax, or
both, and compared with women who never had a positive
blood smear during their pregnancy.
MATERIALS AND METHODS
Study site. Women of the Karen ethnic minority living in
two camps on the northwestern border of Thailand were ex-
amined at the antenatal clinics of the Shoklo Malaria Re-
search Unit. These camps (Shoklo and Maela) had a total
population of 30,000. Médecins sans Frontières was the major
health provider in the camps and a consortium of charities
donated food rations. This is a hill-forested region where
transmission of P. falciparum and P. vivax is low and seasonal.
The maximum recorded entomologic inoculation rates were
approximately 0.5 infectious bites/person/year each for these
two species. Plasmodium malariae and P. ovale are also
found, but rarely. The details of the epidemiology of malaria
in this area have been previously described.23 Before the in-
troduction of early detection and treatment at weekly ante-
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natal clinics, P. falciparum malaria during pregnancy was as-
sociated with maternal death.4 The prevalence of human im-
munodeficiency virus in pregnant women in this population is
extremely low (< 0.2%).
Study design. This was an open, prospective, non-
randomized study. Within the camps, all women were encour-
aged to deliver with trained midwives at the Shoklo Malaria
Research Unit obstetric facility. Attendance was voluntary.
Although Karen women traditionally deliver at home with
traditional birth attendants, the Shoklo Malaria Research
Unit obstetric facility has delivered two-thirds of all babies
(> 8,000) in the camps since 1995. A car is kept on standby for
the transfer to Mae Sot District Hospital for those women
who require emergency caesarean section. The purpose and
the methods of this study were explained to all participants in
their own language. If consent was given when the woman
attended at the time of delivery (initially verbal and later
written), placental specimens and cord and maternal blood
were collected.
The samples were collected in two batches, one of P. fal-
ciparum cases and one of P. vivax cases. All samples collected
were sent to the Tulane National Primate Research Center in
Covington, Louisiana for analysis. The control specimens
were taken from women with no history of malaria; however,
there was a predominance of primiparae among the unin-
fected women.
Ethical approval. This investigation was part of a larger
series of studies aimed at optimizing the drug treatment of
malaria in pregnancy, which were reviewed and approved
both by the ethics committee of the Faculty of Tropical Medi-
cine, Mahidol University (Bangkok, Thailand) and the Karen
Refugee Committee (Mae Sot, Thailand).
Antenatal clinics. On enrollment, a medical record that
included past malaria history and treatment, and obstetric
and medical problems was completed. At each weekly visit,
Karen midwives assessed every woman for temperature and
weight and a malaria smear was prepared for microscopy.
Each woman’s hematocrit was checked every two weeks. The
three species of malaria identified in this study either alone or
in combination were P. falciparum, P. vivax, or P. malariae.
Malaria slide-positive women were treated with antimalarials
appropriate for the species identified. Antimalarials used to
treat P. falciparum included quinine (10 mg/kg three times a
day for seven days), mefloquine (25 mg/kg stat dose), and
artesunate (2 mg/kg once a day for seven days for uncompli-
cated malaria or a treatment failure, or a 4-mg/kg loading
dose, followed by 2 mg/kg once a day for six days for hyper-
parasitemia, defined as > 4% red blood cells [RBCs] parasit-
ized). Some women received combination therapy: clindamy-
cin (5 mg/kg three times a day for seven days) plus quinine or
artesunate, or mefloquine plus artesunate (4 mg/kg/day for
three days). Women with P. vivax or P. malariae infections
were treated with chloroquine phosphate base (10 mg/kg
on days 1 and 2 and 5 mg/kg on day 3). Primaquine was not
used. Antimalarials were provided by the camp dispensaries
only for slide-confirmed cases. Women who attended Shoklo
Malaria Research Unit antenatal clinics and had no history
of malaria and no positive weekly malaria blood smears
throughout their pregnancies and consented to having a blood
sample at delivery fulfilled the inclusion criteria for the un-
infected group.
Labor and delivery. The mother’s peripheral blood was
sampled and a blood smear was made at the start of the
second stage of labor. The cord blood was sampled immedi-
ately after the delivery. Following clamping and cutting of the
cord, the distal end of the cord was held above the level of the
proximal cord and cleaned with gauze. The clamp was re-
leased and the first 5 mL of blood that flowed out was col-
lected into a heparinized tube. The placental samples were
collected within 10 minutes of the completion of the third
stage of labor. Two 1-cm3 sections of placenta were removed
from the maternal surface one-third of the distance between
the cord insertion and edge of the placental disc. The placen-
tal biopsies collected before 1998 were placed in 10% buff-
ered formalin in a 20-mL plastic container, while those col-
lected after 1998 were fixed in Streck tissue fixative (STF)
(Streck Laboratories, Omaha, NE). Thick and thin Giemsa-
stained blood films were made from the mother’s peripheral
venous blood, the infant’s cord blood, and placental blood.
The placental blood was collected by syringe aspiration im-
mediately after the first incision for the biopsy specimen was
made. Thick and thin blood films were examined using 1,000×
magnification with an oil-immersion lens, and peripheral
blood parasite density was calculated as the number of para-
sites present in the thick smear per 500 white blood cells or
the number of infected RBCs per 1,000 RBCs. Thick films
with no Plasmodium parasites observed in 200 fields were
considered negative.
Newborns were weighed within one hour of birth on a
Salter® scale (Salter Weight-Tronix Ltd., Manchester, United
Kingdom) that was accurate to 50 grams. Placentas were
weighed with the cord and membranes attached. The gesta-
tional age of all newborns was estimated by the method of
Dubowitz and Dubowitz between 6 and 24 hours of life.24
Laboratory methods. Placental biopsy specimens were
stored at −25°C for up to 12 months in fixative (10% buffered
formalin or full strength STF) and processed and embedded
in paraffin blocks by standard techniques. Three paraffin sec-
tions, each 5-m thick, were cut and stained with either he-
matoxylin and eosin, Giemsa, or Prussian blue (iron stain).
The hematoxylin and eosin−stained placental specimens were
examined by light microscopy. The histopathologic assess-
ments were conducted blinded to the clinical and obstetric
details. Pigment deposition was assessed by examination of
iron-stained sections to differentiate between hemozoin (ma-
laria pigment [MP]) and hemosiderin, and Giemsa-stained
placental sections were examined for the presence of Plasmo-
dium-infected RBCs in the maternal and fetal blood. All pla-
cental biopsies were examined by an experienced pathologist
who had no prior knowledge of the maternal characteristics,
pregnancy outcome, or malaria episodes in pregnancy. The
methods used were based largely on the methods reported by
Bulmer and others,11,25 Benirschke and Kaufmann,26, Nelson
and others,27 and Davison and others28,29 with slight modifi-
cations. The lesions that have been historically evaluated in
placental malaria by other investigators18,30,31 were also
evaluated in this cohort. Histologic features were scored sub-
jectively from none/minimal to most severe on a scale of 0 to
4 (Table 1). Maternal areas included RBCs, monocytes, poly-
morphonuclear cells, and intervillous fibrin. Fetal areas in-
cluded perivillous fibrin, basal plate fibrin, chorionic villous
stroma, chorionic villous syncytiotrophoblastic layer, Hof-
bauer cells (feto-placental macrophages), and fetal RBCs and
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monocytes in fetal placental vessels (Figure 1). The amount of
MP was scored subjectively and the sum of the pigment scores
for all areas examined was assigned as the total MP score for
each case.
The classification of Bulmer and others was also applied to
the specimens.11 Briefly, placentas were classified as not in-
fected if there was no evidence of parasites or MP, as acute
infections if there was evidence of parasites and absent or
minimal pigment deposition within fibrin, as chronic active
infection if there were parasites and a significant amount of
pigment deposition, and as chronic past infection if there was
pigment but no parasites.
Definitions. Low birth weight was defined as a birth weight
less than 2,500 grams. Premature infants were those with a
gestational age less than 37 weeks. Intra-uterine growth re-
tardation referred to those infants who were term ( 37
weeks gestation) and with a low birth weight. Abortion was
defined as delivery before 22 completed weeks of pregnancy.
Stillbirth was defined as delivery of a dead infant of greater
than 22 weeks gestational age with no heartbeat or respira-
tion. Anemia was defined as an hematocrit less than 30%. A
malaria episode was defined by a positive parasitemia, re-
gardless of symptoms. A symptomatic malaria episode was
defined by fever (oral temperature > 37.5°C) or a history of
fever in the presence of parasitemia. Massive chronic inter-
villositis was defined in placental specimens as a prominent
inflammatory cell infiltrate in the intervillous space (IVS),
composed mainly of mononuclear cells including monocytes/
macrophages and lymphocytes.32
Statistical analysis. Data were analyzed using the statistical
program SPSS for Windows (SPSS Inc., Chicago, IL) and
Epi-Info (Centers for Disease Control and Prevention, At-
lanta, GA). The distribution of mononuclear cells/high-power
field, polymorphonuclear cells/high-power field, and syncytial
knots/field (40×) were normalized by log transformation.
Thus, mean values refer to the geometric mean. Normally
distributed continuous data were compared between different
groups of patients by the Student’s t-test and non-normally
distributed continuous data were compared by the Mann-
Whitney U test. Categorical data were analyzed by the chi-
square test or Fisher’s exact test. Factors possibly associated
with higher MP scores were analyzed by univariate analysis.
RESULTS
Between February 1995 and February 2002, there were 213
deliveries from which samples of placental tissue were ana-
lyzed. Nine samples were excluded from the histopathologic
analysis: two with very poor fixation, six with maternal hy-
pertension, and one with bacterial intervillositis. This left 204
samples for analysis. None of the women had gestational dia-
betes and no infants were stillborn.
Malaria groups. The samples have been divided into four
malaria groups according to the results of the prospective
follow-up of the women from weekly malaria smears at the
antenatal clinics: 1) women who had only P. falciparum (PF),
2) women who had only non-P. falciparum (nonPF), 3)
women who had mixed infections of both PF and P. vivax
during pregnancy either on separate occasions or at the same
time (mixed), and 4) women with no positive peripheral ma-
laria smears from weekly screening in pregnancy (unin-
fected). Overall, there were 175 women with 337 treated epi-
sodes of malaria and 29 women with no malaria infections
documented in pregnancy. Their characteristics and birth out-
comes are summarized in Table 2. The nonPF group included
30 women: two with P. malariae infections and 28 with
P. vivax infections. There were no P. malariae infections in
the mixed group. The uninfected group was significantly
younger (P  0.05, for all comparisons) and had a greater
proportion of primigravidae compared with the PF, nonPF,
and mixed groups (P  0.014, P  0.069, P  0.011), re-
spectively, but this did not affect the results of the histopath-
ologic examination of the placenta. There were no significant
differences in the proportion of women in each malaria group
who delivered within seven days of the last episode of ma-
laria. There were no significant differences in the number of
consultations between the groups.
TABLE 1
Scoring system for the evaluation of placental sections for presence of malaria-associated histopathologic changes
Abnormality Mild → Most severe
Ranking 0 1 2 3 4
Perivillous fibrin
deposition
Involving <5% Involving 5–30% Involving 30% – –
Fibrinoid necrosis None One to a few
multifocal areas

























Mild but easy to
identify without
extensive exam








Syncytial knots Counted numerically in three 40× fields with a range and then average number per field calculated
Mononuclear cells Counted numerically in 10 high-power fields (HPFs) (100× oil immersion) and expressed as an average number/HPF
Polymorphonuclear
cells
Counted numerically in 10 HPFs (100× oil immersion) and expressed as an average number/HPF
Parasites counted in Negative Rare Low High
100 fields
None 1 to a few very rare 1–2/HPF Large numbers in every HPF
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Parasites. Plasmodium-infected RBCs observed in periph-
eral, cord, and placental blood smears. There were 3 (1.5%),
22 (10.8%), and 19 (9.3%), mother, cord, and placental blood
smears, respectively, that were unavailable (poor quality, bro-
ken, or lost smears) for analysis. Parasitemia at the time of
delivery was found in 19 (9.5%) peripheral, 12 (6.5%) pla-
cental and 2 (1.1%) cord blood smears. All 12 women with
positive placental blood parasitemia and the two women with
positive cord blood parasitemia had concurrent positive pe-
ripheral blood parasitemia. All placenta (and cord) blood
smear-positive cases were associated with recent parasitemic
malaria, occurring a median of 1 (range  0−3) day before
delivery. In women who had malaria at any time during their
pregnancy, the placental blood smear parasite positivity rate
was 6.9% (12 of 173, 95% confidence interval [CI] 
3.6−11.8%). None of the uninfected or P. malariae-infected
women had malaria parasites detected in cord, placental, or
peripheral blood smears at delivery.
Parasites in placental histopathology sections. Parasites
were not found in the 29 women in the uninfected group or in
the P. malariae-infected women by histopathologic examina-
tion (Table 3). In women who had malaria anytime in preg-
nancy, the placental histopathologic parasite positivity rate
was 21.3% (37 of 174, 95% CI  15.8−27.9%). When para-
sites were detected in the maternal blood within the IVS of
the placenta by histopathology, they were predominantly re-
FIGURE 1. Schematic representation of the human placenta, with the inset showing a cross-section of terminal villi. 1  The villi are composed
of fetal connective tissue and are covered by trophoblasts. The trophoblast is the parenchyma of the placenta. It is the tissue through which
exchanges must occur, and it is involved in the production of placental hormones, both steroids and polypeptides. Parasites and pigments were
evaluated in both maternal and fetal tissues. 2  The cytotrophoblast (Langhan’s layer) is made up of distinctly separate cells that form a
continuous layer in early pregnancy. Later in pregnancy, this layer is reduced to a few scattered large pale cells with pale nuclei. Cytotrophoblastic
prominence is an increase in their numbers. 3  The severity of polymorphonuclear and mononuclear cell infiltrates is evaluated within the
intervillous space (IVS). Most villi are free in the IVS and are bathed in blood from the maternal vessels. 4  In the area of the trophoblastic
membrane placental tissue is evaluated for 1) fibrin-type fibrinoid: a blood-clotting product free of the extravillous trophoblast cells and usually
in contact with the IVS and 2) matrix-type fibrinoid (embedded with trophoblast cells) and that itself is a secretory product of these cells. Fibrinoid
necrosis of the villi occurs when matrix-type fibrinoid replaces villous stroma, leaving an intact trophoblastic surface. Perivillous fibrinoid is a
matrix-type fibrinoid that replaces the trophoblastic cover of the villi. 5  The outer covering of the villi is the syncytiotrophoblast, a syneytium
with many dark-staining nuclei. During the latter half of pregnancy, groups of aggregated nuclei may project at the surface forming syncytial knots.
(Reproduced with permission of Taylor & Francis, London, United Kingdom, from Duffy PE, 2001. Immunity to malaria during pregnancy:
different host, different parasite. Duffy PE, Fried M, eds. Malaria in Pregnancy: Deadly Parasite, Susceptible Host, 103.)
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ported as rare (64.9% [24 of 37]) and only P. falciparum
infection accounted for high placental parasite densities, re-
ported in 16.2% (6 of 37) of cases. Even in those with high-
density parasites there was no evidence of cytoadherence or
apparent binding between infected RBCs and the syncytio-
trophoblast cell layer that surrounds the placental villi. Al-
though described by many groups as an in vitro or in vivo
phenomenon,33,34 we were unable to find any unequivocal
reports of in vivo cytoadherence of P. falciparum-infected
RBCs in the placenta of malaria-infected women. The inter-
val from the last malaria infection (positive peripheral blood
smear) until delivery for women whose placentas were para-
site positive by histopathology was a median of 5 (range 
0−129) days. Since 21 (56.8%) of these women were positive
TABLE 3









Mononuclear cells/high-power field, 3.5‡ 2.7 3.1 3.2
Geometric mean (range) (1.5–95.5) (1.5–4.8) (1.2–9.1) (1.5–8.7)
Polymorphonuclear cells/high-power field, 3.4‡ 2.6 3.4‡ 3.5
Geometric mean (range) (1.3–14.5) (1.2–3.9) (1.7–7.8) (1.8–8.3)
Syncytial knots, 14‡ 11 13 11
Geometric mean (range)* (4–45) (4–30) (4–37) (3–31)
Perivillous fibrin involving > 30%, % 31.1‡ 3.6 23.6‡ 13.8
(28/90) (1/28) (13/55) (4/29)
Fibrinoid necrosis affecting > 50%, % 12.2 0 9.1 6.9
(11/90) (0/28) (5/55) (2/29)
Cytotrophoblastic cell prominence 18.9‡§ 0 12.7§ 0
(most of the villi involved), % (17/90) (0/28) (7/55) (0/29)
Total MP score, median (range) 2 [0–18]‡§ 0 [0–4]§ 3 [0–13]‡§ 0 [0]
Parasites positive by histopathology, % 24.7‡§ 3.6 25.5‡§ 0
(22/89) (1/28) (14/55) (0/29)
* PF  Plasmodium falciparum, PV  P. vivax; MP  malaria pigment. There were no significant differences for all comparisons of PF versus mixed groups.
† Excludes P. malariae (n  2)
‡ Significantly higher than the PV group (P < 0.05).
§ Significantly higher than the uninfected group (P < 0.05).
TABLE 2









Mother demographic and malaria episode characteristics
Age, years 25 (6) [16–41] 26 (7) [17–40] 27 (7) [15–45] 22 (6) [16–35]
Gravidity, median 2 [1–10] 2 [1–8] 3 [1–10] 1 [1–6]
Proportion primigravidae {n} 31.1 {28} 33.3 [10] 29.1 {16} 58.6 {17}
Gestational age (weeks) at first consultation, median 14.8 [3.7–39.8] 13.6 (6.2–34.5] 14.1 [1.7–34.5] 13.6 [3.8–39.3]
Number weekly consults, median 19 [1–33] 21 [4–33] 21 [3–36] 22 [1–34]
Number of malaria infections detected and treated 1 [1–4] PV 2 [1–4] Total 3 [1–7]† 0
antenatally, median PM 1 [1] PF 1 [1–3]
PV 1 [1–6]
Mixed 1 [1]
Proportion with at least 1 symptomatic malaria episode 63.3 {57/90} 53.6 [15/28] 70.9 {39/55}
Proportion with malaria episode in last 7 days of pregnancy 20.0 {18/90} 20.0 {6/30} 34.5 {19/55} NA
Median no. of days from delivery to last malaria infection 101 [0–252] 37 [0–146] 29 [0–175] NA
Estimated gestational (weeks) age at first malaria episode 20 (10) [4–41] 27 (10) [3–40] 19 (9) [5–40] NA
Mean hematocrit at delivery 31.5 (4.8) 36.5 (3.2) 31.9 (3.8) 34.3 (3.6)
Proportion of women anemic at delivery 27.3 (24/88) 0 27.8 (15/54) 13.8 (4/29)
Birth outcomes
Viable single births 89 (1 abortion) 29 (excluding twins) 55 29
Birth weight, grams 2,842 (530) 2,912 (314) 2,875 (414) 2,922 (340)
[600–3,900] [2,400–3,750] [2,000–3,850] [2,300–3,650]
Gestational age, weeks 39.0 (2.5) 39.9 (1.3) 39.3 (1.2) 39.4 (1.1)
[24.0–41.8] [36.1–41.5] [36.2–41.7] [36.2–40.9]
Proportion of low birth weight {n} 16.9 {15} 3.4 {1} 12.7 {7} 10.3 {3}
Proportion of premature infants {n} 11.2 {10} 3.4 {1} 5.5 {3} 3.4 {1}
Proportion of IUGR {n} 10.1 {8} 3.6 {1} 9.6 {5} 10.7 {3}
Placental weight, grams 487 (94) 517 (105) 510 (104) 488 (62)
[100–700] [350–800] [300–800] [300–600]
Fetal/placenta weight ratio {n} Primigravida 5.7 {21} 5.9 {9} 5.7 {14} 6.1 {16}
Multigravida 6.1 {57} 5.8 {17} 5.8 {38} 6.0 {12}
* PF  Plasmodium falciparum; NonPF  non-P. falciparum; Mixed  both PF and P. vivax (PV) during pregnancy either on separate occasions or at the same time; Uninfected  no positive
peripheral malaria smears from weekly screening during pregnancy; PM  P. malariae; NA  not applicable; IUGR  intrauterine growth retardation. Data are the mean (SD) [range] unless
otherwise stated.
Values in braces ({ }) refer to the actual number.
† One is possible in the range occurring in the woman coinfected with PF and PV.
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in the last seven days of pregnancy, this finding of placental
parasites was not unexpected. For the remaining 16 women,
7 (18.9%) had their last episode detected from 11 to 30 days
from delivery and 9 (24.3%) from 31 and 129 days from de-
livery. The sample size was too small to compare the effects of
different drug treatments for these women.
Histopathologic examination identified a greater propor-
tion of cases with parasites in the placenta (n  37) than did
the placental blood smear (n  12). The relationships be-
tween histopathology and blood smear results (peripheral,
placenta, and cord) at the time of delivery are summarized
in Table 4 for women for whom data are available. In 5 cases
(1 P. falciparum and 4 P. vivax) women were positive by
placenta blood smear and negative by histopathologic exami-
nation, and in 24 cases women were negative by placental
blood smear and positive by histopathologic examination
(Table 4). Histopathology was more likely to agree with the
placental blood smear result when the last infection before
delivery was P. falciparum, rather than P. vivax. The plasmo-
dium species were not differentiated by the histopathologic
examination.
Estimated population placental and histopathologic para-
site-positive rate. During the course of this study, there were
1,663 women with documented malaria (P. falciparum and
P. vivax) and 8,310 women who delivered, having attending
the weekly Shoklo Malaria Research Unit antenatal clinics.
Using the assumption that the women who attended the an-
tenatal clinics who never had malaria detected would also
have negative placental smears (since all in the uninfected
group were negative in this study), the population parasite
(all species) placental malaria smear positivity rate was esti-
mated as 0.069% (95% CI  0.04−0.12) × 1,663/8,310 
1.4% (95% CI  0.72−2.36). The histopathologic examina-
tion placental parasite positivity rate was significantly higher
at 0.213% (95% CI  0.158−0.279) × 1,663/8,310  4.3%
(95% CI  3.2–5.6).
Congenital malaria. There were three cases (2 definite and
1 probable) of congenital malaria detected by infant periph-
eral blood smear: two P. falciparum (day 0 of life, parasitemia
 36,000/ L and 216/L) and one P. vivax (day 14 of life
therefore probable, parasitemia  540/L). The mothers
were on their second (quinine), fourth (mefloquine), and
first (chloroquine) days of treatment. The P. vivax case had
negative peripheral blood smears on days 0 and 7 of life. All
three cases had placental blood smear parasitemias. Only the
P. vivax case also had a positive cord blood parasitemia. Both
babies with P. falciparum were symptomatic for malaria and
one died of severe malaria on day 6 of life. The infant who
survived was the only one to have parasites by histopathol-
ogy. In this case, there were more infected RBCs than unin-
fected RBCs in the IVS and no parasites were observed
within fetal blood vessels. The pigment was not in fibrin, only
in maternal RBCs and white blood cells, indicating an acute
case of severe malaria.
Malaria pigment. Of the 204 placental samples 52% (106 of
204) were contaminated by formalin pigment (including
samples of the uninfected group) due to improper fixation
and these could not be used to reliably assess MP. When the
98 women with reliable MP were compared with the 106
women with unreliable MP, no significant differences in their
baseline characteristics were found.
Malaria pigment was observed in several discrete locations;
maternal erythrocytes in association with intraerythrocytic
parasites, maternal white blood cells (both monocytes and
polymorphs) following phagocytosis, and both maternal and
fetal peri-villous fibrin and the basal plate fibrin (these were
most frequently observed), and to a lesser extent in the cho-
rionic villous stroma and chorionic villous syncytiotropho-
blastic layer and fetal Hofbauer cells (Figure 2). There was
no MP deposition in the uninfected group. There was also no
MP deposition in either of the placentas of the two P. ma-
lariae cases and they have not been included for further analy-
sis of MP.
The species of malaria affected the locations where MP
could be identified (Figure 2). While the PF and mixed groups
tended to have the same distribution of MP, in the P. vivax-
infected group the MP deposits were found less widely
distributed and in lower amounts, except for in maternal
monocytes.
Women in the PF and mixed groups had higher amounts of
MP than those in the P. vivax-infected group (Figure 2). The
total MP score was significantly higher in the P. vivax-infected
group compared with the uninfected group (P  0.004)
(Table 3) and was increased significantly (P < 0.05) 1) in
women with high maternal P. falciparum parasitemia, 2) in
primigravidae, 3) in symptomatic cases, 4) when malaria oc-
curred during the seven days before delivery (Figure 3), and
5) in women with high mononuclear cell counts in the IVS.
TABLE 4






result Negative % (n)
Positive
Plasmodium falciparum positive % (n) P. vivax positive % (n)
Mother Peripheral + 14 (25/179) 91.7 (11/12) 14.3 (1/7)
− 86 (156/179) 8.3 (1/12) 85.7 (6/7)
Placenta + 14 (24/170) 87.5 (7/8) 0
PF  12, PV  1, mixed  11# PF  5, mixed  2† –
− 86 (146/170) 12.5 (1/8) 100 (4/4)
PF  60, PV  24, mixed  38, uninfected  24 PF  1 PV  3, mixed  1‡
Cord + 17 (30/177) 100 (1/1) 0
− 83 (157/177) 0 100 (1/1)
* n  women with both smear and histopathology results available for comparison; PF  P. falciparum; PV  P. vivax. For women in the mixed group, the last recorded infections in pregnancy
were PF in two cases, PV in seven cases, and mixed in two cases.
† PF for both cases.
‡ PV for one case.
# PF in 2 cases, Rv in 7 cases and mixed in 2 cases.
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For women infected with P. vivax, no identifiable factors were
significantly associated with increased total MP scores prob-
ably because of the small numbers.
Other histopathologic effects on the placenta. Apart from
the presence of parasites and the total pigment score (detailed
earlier), the only other significant malaria placental change
compared with the control group was greater cytotrophoblas-
tic prominence in the PF and mixed groups (Table 3).
Effects of gravidity and time of infection on placental
changes. Since there were no significant differences between
the histopathology of the PF and mixed groups (Table 3),
these groups were pooled for the analysis of the effects of
gravidity and time of infection on placental histopathology.
Primigravida scored significantly higher than multigravida
for the following parameters: total median MP score  5
(range  0−18) versus 1.0 (range  0−13); P  0.001; pres-
ence of parasites by histopathology  41.9% (18 of 43) versus
17.8% (18 of 101); P  0.003; and geometric mean number of
mononuclear cells  4.1 (range  1.7−95.5) versus 3.1 (range
 1.2−20.0); P  0.017. Polymorphonuclear cells, syncytial
knots, perivillous fibrin, fibrinoid necrosis, and cytotropho-
blastic prominence did not differ significantly between primi-
gravida and multigravida.
The pooled PF and mixed groups was subdivided according
to the time of the last malaria episode in pregnancy: malaria
in the previous seven days and malaria before the last seven
days of pregnancy. The geometric mean mononuclear cell
count in the IVS was significantly higher in the former group:
5.0 (range  1.5−95.5) compared with 3.1 (range  1.2−20.0)
in the latter group (P < 0.001). The median MP score was also
significantly higher in the group with more recent infections
(6 [range  0−18] versus 2.0 [range  0−9]; P  0.006). No sig-
nificant differences were observed when other aspects of pla-
cental histopathology were compared using this subdivision.
Bulmer classification. When the histopathologist applied
the Bulmer classification to 98 placental samples where pig-
ment could be assessed confidently, all specimens in the un-
infected group (n  19) were classified as Bulmer negative
(absence of parasites and pigment). A large proportion of the
placentas from women with confirmed malaria were also clas-
sified as Bulmer negative: PF  34.5% (10 of 29), nonPF 
66.7% (20 of 30), and mixed  30.0% (6 of 20). Overall,
nearly half of the women who had malaria during pregnancy
(n  79) were classified as Bulmer negative: 45.6% (36 of 79).
If this comparison was confined to women who had at least
one P. falciparum infection in pregnancy, then 27.1% (16 of
59) of the cases would have been misclassified using this system.
Massive chronic intervillousitis (MCI). There were three
(1.7%, 3 of 175) women who had classic MCI in association
with malaria in pregnancy (see Materials and Methods). All
cases were in primigravida with acute symptomatic P. falci-
parum malaria that was being treated at the time of delivery.
None had a documented episode of P. vivax malaria at any
time during pregnancy. Deliveries occurred on days 2 (n  2)
and 4 (n  1) of treatment. All three babies were of low birth
weight and two were also premature, both of whom died. All
three women who had MCI had parasites detected by histo-
pathology and one of these was also positive by placental
smear.
DISCUSSION
This is the first investigation of the placenta histopathology
in P. falciparum and P. vivax malaria-infected pregnant
women in an area of low transmission. It also differs from
previous studies because all women were screened for malaria
each week by peripheral blood smears and all women with
malaria positive smears were treated promptly regardless of
symptoms. Thus, there was an accurate history of malaria
infections preceding delivery. It differs from the study by
Watkinson and Rushton17 in that women were screened for
malaria on average 20 times, compared with 8 times in The
Gambia, and because treatment of women on the borders of
FIGURE 3. Proportion of placentas with malaria pigment in rela-
tion to the timing of Plasmodium falciparum infection. Black bars 
P. falciparum  7 days before delivery; grey bars  P. falciparum
> 7 days before delivery. For definitions of abbreviations, see Fig-
ure 2. Only statistically significant (P < 0.05) differences are shown.
*P. falciparum  7 days before delivery group significantly higher
than the P. falciparum > 7 days before delivery group.
FIGURE 2. Proportion of placentas with malaria pigment in rela-
tion to the type of Plasmodium infection during pregnancy. Black
bars  P. falciparum; gray bars  mixed infections; white bars 
P. vivax. Mat  maternal; Fet  fetal; HB  Hofbauer cells (feto-
placental macrophages); RBCs  red blood cells; PMN  polymor-
phonuclear cells; PVF  perivillous fibrin; CVS  chorionic villous
stroma; Mono  monocytes. IVF  intervillous fibzin; BPF  basal
plate fibzin; CVSL  chorionic villous syncytiotrophoblastic layer.
Only statistically significant (P < 0.05) differences are shown. #P.
falciparum group significantly higher than the P. vivax group. ∧Mixed
infection group significantly higher than the P. vivax group.
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Thailand is complicated by multidrug resistance in P. falci-
parum. In this area, the first line antimalarial agent for preg-
nant women, supervised quinine (10 mg/kg, three times a day
for seven days), has a polymerase chain reaction−confirmed
failure rate of 33% (95%CI  9.2−56.7).35
Enormous numbers of parasites and macrophages in the
IVS and increased fibrinous deposits containing pigment and
macrophages with focal necrosis of the adjacent syncytiotro-
phoblast have consistently been reported in previous stud-
ies,31 but were uncommon in the present series. The total MP
score was the most significant marker of previous malaria
infection, occurring in approximately 50% of women with
documented malaria and never present in the uninfected
women. Large numbers of placental parasites, as are reported
commonly from areas of high transmission, were extremely
rare in the current series. Parasites were predominantly re-
ported as rare and high counts only occurred in women in-
fected with P. falciparum, not P. vivax. Cytotrophoblastic
prominence was also significantly higher in women with P.
falciparum infection than in uninfected women. Increased
numbers of mononuclear cells in the IVS became significantly
higher than in the uninfected women only when the analysis
was confined to P. falciparum infection in the last seven days
of pregnancy. The rate of massive chronic intervillositis was
also very low (1.7%, 3 of 175) when compared with the largest
reported series from Tanzania, (6.3%, 74 of 1,179).
Despite weekly screening and prompt antimalarial treat-
ment, 21% of the women still had parasites observed by his-
topathology in their placenta at the time of delivery. The
presence of parasites in the placenta in 14% of the women
whose infection had been cleared from the peripheral blood
(Table 4) may be indicative of drug resistance and may be the
result of the modified pharmacokinetic and pharmacody-
namic properties of antimalarial drugs in pregnancy.36−39 In
either case, malaria parasites are able to persist in the pla-
centa despite being cleared form the peripheral blood, at least
below the level of detection by microscopy, as suggested in an
earlier case report.40
The malaria-associated placental changes occurred only in
women whose malaria infections were detected antenatally or
at delivery, unlike the Watkinson and Rushton cohort,17 in
which 69% (27 of 39) of the women had a pigmented placenta
but no peripheral parasitemia recorded during pregnancy.
Thus in this series, there was no evidence of cryptic malaria;
all infections became patent.
These differences in placental histopathology can, in part,
be accounted for by the attack rates experienced in pregnancy
in high and low transmission areas. However, this does not
explain why there is such a big difference in placental
changes, but similar reported reductions in birth weights.4 In
this cohort, placental changes were most marked when infec-
tion was recent, often while women were receiving treatment
for a malaria episode. This suggests that early detection and
treatment allows the placenta to recover as hypothesized by
Watkinson and Rushton.17 The effect on birth weight reduc-
tion may result not from the physical presence of irreversible
placental changes but from the acute insult. The immune re-
sponse via mechanisms such as local or systemic release of
pro-inflammatory cytokines may also play an important role
in birth weight reduction.41−43
Placental changes (increased number of inflammatory cells,
fibrin deposition, cytotrophoblastic prominence, and syncytial
knotting) were significantly greater in women infected with
P. falciparum compared with women infected with P. vivax.
This again implies that persistent pathologic damage to the
placenta is not the most determinant factor in birth weight
reduction since infants of women infected with P. vivax dur-
ing pregnancy also show significant birth weight reduction.5
This is similar to a report by Jelliffe on 23 cases of infection
with P. malariae during pregnancy in Uganda.22 Infections
with both species (P. falciparum and P. vivax) during the
antenatal period did not result in placental changes different
from those of infection with P. falciparum alone. Placental
changes (increased inflammatory cells, fibrin deposition, cy-
totrophoblastic prominence and syncytial knotting) were sig-
nificantly greater in women infected with P. falciparum com-
pared with women infected with P. vivax, which again implies
that persistent pathologic damage to the placenta is not the
most determinant factor in birth weight reduction.
This study shows that malaria in pregnancy commonly re-
covers without leaving a residue of parasites and pigment in
placental tissues. Absence of parasites and pigment on pla-
cental pathology is the Bulmer definition of “not infected”
placentas.25 Schulman and others cite “placental histology as
the most sensitive measure currently available for the diag-
nosis of malaria in pregnancy”.8 Placental malaria has been
used as a major end point in intervention trials in preg-
nancy.44−47 The data of Watkinson and Rushton in The Gam-
bia17 (a high transmission setting) and the data presented
here contradict this as a sensitive marker of malaria-
associated pathologic processes, particularly in areas of lower
transmission. More than one-fourth of the women with docu-
mented P. falciparum infection during pregnancy would have
been classified as negative using the Bulmer classification in
this cohort (Bulmer score: sensitivity  66%, specificity 
100%). A similar proportion of women (24%, 12 of 50) in the
cohort of Watkinson and Rushton17 with treated peripheral
parasitemia during pregnancy also would have been classified
as negative. Frequent peripheral malaria smears in pregnant
Karen women proved to be a much more sensitive measure of
malaria infection during pregnancy than placental histopath-
ologic classification. Thus, malaria in the placenta at delivery
should not be considered a reliable proxy for malaria during
pregnancy.
In a normal pregnancy, the fetus gains an average of
300−400 grams between 36 and 38 weeks and again between
38 and 40 weeks of gestation. Anemia in the mother at deliv-
ery is a major factor in post-partum hemorrhage, one of the
leading two causes of maternal death in developing countries.
Two doses of intermittent sulfadoxine-pyrimethamine (SP)
preventive treatment are widely recommended at the begin-
ning of each trimester (but not at term) to reduce low birth
weight and anemia. Our data suggest that dosing closer to
delivery may have added benefit but alternatives to SP are
needed. The findings presented here advocate more active
antenatal screening and emphasize the importance of treating
all episodes of parasitemia in pregnant women irrespective of
symptoms with an effective antimalarial drug.
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